Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

US Judge Upholds Validity Of Merck's Vytorin Patent

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/28/2012 | 12:03am CEST
   By Peter Loftus 
   Of  
 

A federal judge has upheld the validity of a U.S. patent covering Merck & Co.'s (>> Merck & Co., Inc.) Vytorin cholesterol-lowering drug, which could stave off competing generic copies for several years.

In an opinion released Friday, U.S. District Judge Jose Linares in federal court in Newark, N.J., said a patent for Vytorin was valid and enforceable.

Merck, based in Whitehouse Station, N.J., said in a recent regulatory filing it expects its U.S. exclusivity for Vytorin and a related drug, Zetia, to expire in April 2017.

Mylan Inc. (MYL) had applied for U.S. Food and Drug Administration approval to sell a generic version of Vytorin before its patent protection expired, arguing that the patent was invalid and unenforceable.

Schering-Plough, which was acquired by Merck in 2009, filed a patent-infringement lawsuit against Mylan in late 2009, seeking to block Mylan's product. A trial was held in December 2011, leading to Judge Linares's opinion Friday.

On a conference call with analysts Friday morning, Merck Chief Executive Kenneth Frazier said he was anticipating a favorable decision. "We believe this is a patent that is valid and enforceable," he said.

A Mylan spokeswoman couldn't immediately be reached.

Earlier Friday, Merck reported first-quarter Vytorin sales of $444 million and Zetia sales of $614 million.

Merck previously reached a settlement of patent litigation for Zetia with generics manufacturer Glenmark Pharmaceuticals. The pact will allow Glenmark to sell generic Zetia in December 2016, subject to final regulatory approval.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; [email protected]

Stocks mentioned in the article : Merck & Co., Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK & CO., INC.
05/23 MERCK : FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Adult and Pedia..
05/23DJMERCK : FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update
05/23DJMERCK : FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects
05/23 MERCK : Announces Third-Quarter 2017 Dividend
05/23 MERCK & CO., INC. (NYSE : MRK) ISENTRESS Receives Positive Opinion From CHMP
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/23 MERCK : FDA Grants Priority Review to Merck’s Supplemental Biologics Licen..
05/22 MERCK : Announces Presentation of Phase 2 Results for MK-7264, an Investigationa..
05/22 MERCK : Contractor Hits 5 Million Safe Hours
05/20 MERCK : CHMP Adopts Positive Opinion For Isentress 600 Mg In EU
More news
Sector news : Pharmaceuticals - NEC
05/23DJALEXION PHARMACEUTICALS : Shakeup Continues as Four Executives Exit -- 2nd Updat..
05/23DJALEXION PHARMACEUTICALS : Shakeup Continues as Four Executives Exit -- Update
05/23DJALEXION PHARMACEUTICALS : Management Shakeup Continues as Four More Executives E..
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/23DJASTRAZENECA : Says Bydureon Trial Meets Safety Objectives; No Significant CV Red..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
05/23 PFIZER VS. MERCK : 4 Reasons One Is The Superior Choice
05/23 FDA OKs Merck's Keytruda for certain solid tumors
05/23 Merck & Co's (MRK) Annual Shareholders Meeting Brokers Conference (Transcript..
05/23 Merck declares $0.47 dividend
05/23 FDA tags Merck's Keytruda supplemental BLA for Priority Review for gastric/es..
Advertisement
Financials ($)
Sales 2017 39 930 M
EBIT 2017 13 655 M
Net income 2017 7 128 M
Debt 2017 942 M
Yield 2017 2,91%
P/E ratio 2017 24,85
P/E ratio 2018 18,83
EV / Sales 2017 4,45x
EV / Sales 2018 4,32x
Capitalization 176 555 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 69,3 $
Spread / Average Target 7,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.9.65%175 160
JOHNSON & JOHNSON10.46%342 817
ROCHE HOLDING LTD.14.79%237 610
NOVARTIS AG6.28%213 719
PFIZER INC.-1.05%191 279
SANOFI14.93%124 306
More Results